cagrilintide semaglutide combination phase 3 2024 New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk What are the side effects

This blend comes from a GMP-compliant facility in the USA with a purity level of 99%

Pregnancy Safety Registries: Ongoing pharmacovigilance and pregnancy exposure registries are necessary to define teratogenic risk and optimal discontinuation intervals

The deltoid is easily accessible without needing to undress the patient extensively, making it a convenient site for quick and effective injections, especially in outpatient settings

Intranasal technique: Clear nasal passages before administration Tilt head slightly forward Insert spray nozzle into nostril, angling slightly away from the nasal septum Administer one to two sprays per nostril Breathe gently through the nose for 10 to 15 seconds after application Avoid blowing the nose for several minutes post-administration Subcutaneous Injection (Alternative) When nasal spray formulations are unavailable, Selank can be administered subcutaneously